For all publications, please see the PubMed listing
About Dr. Kallas
Dr. Romy Kallas is a rheumatologist at Hospital for Special Surgery, specializing in the care of patients with autoimmune and systemic rheumatic diseases, with a particular focus on systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). She works closely with multidisciplinary teams at NewYork-Presbyterian/Weill Cornell Medicine to deliver comprehensive, individualized care.
Dr. Kallas earned her medical degree from the American University of Beirut. She completed her rheumatology fellowship at Hospital for Special Surgery and NewYork-Presbyterian/Weill Cornell Medicine. She also pursued a dedicated lupus clinical and research fellowship at Johns Hopkins University and holds a Master's degree in Clinical and Translational Investigation from Weill Cornell Medicine.
Dr. Kallas is actively involved in clinical research aimed at improving therapies for lupus and lupus nephritis. She participates in ongoing clinical trials and is committed to translating scientific advances into better outcomes for patients. Her approach emphasizes compassionate, personalized care and patient empowerment.
Special Expertise
Systemic Lupus Erythematosus (SLE)
Lupus Nephritis
Lupus Clinical Trials
Lupus and Pregnancy
Anti-phospholipid Syndrome
Patient ratings for Dr. Kallas
Insurance
This provider is currently in the process of joining the networks of many commercial insurance plans and should show as a participating provider soon.
If your insurance is not listed, please call our office if you have questions regarding your insurance coverage. If you have out-of-network benefits, then your insurance may reimburse you for a portion of your office visit.
Credentials
Appointments
Attending Physician, Hospital for Special Surgery
Assistant Professor of Medicine, Weill Cornell Medical College
Assistant Attending Physician, NewYork-Presbyterian Hospital
Affiliations
American College of Rheumatology
Lupus Clinical Investigators Network
Certifications
American Board of Internal Medicine, 2022
American Board of Rheumatology, 2024
Awards
Best Abstract Presentation Award, Sharpe- Strumia Research Foundation, 2022
Best Poster Presentation Award, Conference of Clinical Rheumatology, 2019
Advanced Fellowship Award, Diana Tamari Sabbagh Scholars Program, 2018
Eighth EULAR Scientifically Endorsed Course on Systemic Lupus Erythematosus Scholarship, European League
Against Rheumatism (EULAR), 2017
Education
Medical
American University of Beirut School of Medicine, 2012
Internship
Internal Medicine, American University of Beirut Medical Center, 2013
Internal Medicine, Lankenau Medical Center, Wynnewood, PA, 2021
Residency
Internal Medicine, American University of Beirut Medical Center, 2015
Internal Medicine Chief Residency, American University of Beirut Medical Center, 2016
Internal Medicine, Lankenau Medical Center, Wynnewood, PA, 2022
Fellowship
Rheumatology, American University of Beirut Medical Center, 2018
Clinical and Research Lupus Fellowship, Johns Hopkins University, Baltimore, MD, 2020
Rheumatology, Hospital of Special Surgery/ Weill Cornell Medical Center, New York, NY, 2025
State Licensure
New York
Languages
English, Arabic, FrenchFor My Patients
Publications by Dr. Kallas
Selected Journal Articles
Selected Presentations
.
Industry Relationships
HSS has a long history of supporting appropriate relationships with industry because they advance HSS's mission to provide the highest quality patient care, improve patient mobility, and enhance the quality of life for all, and to advance the science of orthopedic surgery, rheumatology, and their related disciplines through research and education.
As of October 17, 2025, Dr. Kallas reported no relationships with the healthcare industry.
HSS and its physicians make this information available to patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest and Commitment Policy prohibits physicians from collecting royalties on products they develop that are used on patients at HSS.